No articles found for this sector...

================================================================================

No articles found for this sector...

================================================================================

[TITLE]Oncology Collaboration and Licensing Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 3,000+ Deals by Company A-Z, Therapy Focus and Technology Type:
[TEXT]
Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2020-2025" has been added to ResearchAndMarkets.com's offering.

Fully revised and updated, the report provides details of 3,000+ oncology deals from 2020 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the world's leading biopharma companies.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where
[Source link]: https://www.globenewswire.com/news-release/2025/11/19/3191217/28124/en/Oncology-Collaboration-and-Licensing-Analysis-Report-and-Directory-2025-Upfront-Milestone-and-Royalties-for-3-000-Deals-by-Company-A-Z-Therapy-Focus-and-Technology-Type.html


[TITLE]Autoimmune Collaboration and Licensing Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 943 Deals by Company A-Z, Therapy Focus and Technology Type:
[TEXT]
Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

Fully revised and updated, the report provides details of 943 autoimmune deals from 2016 to 2025.

Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the world's leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where
[Source link]: https://www.globenewswire.com/news-release/2025/11/19/3191215/28124/en/Autoimmune-Collaboration-and-Licensing-Analysis-Report-and-Directory-2025-Upfront-Milestone-and-Royalties-for-943-Deals-by-Company-A-Z-Therapy-Focus-and-Technology-Type.html


[TITLE]Psychiatry Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 569 Deals by Company A-Z, Therapy Focus and Technology Type:
[TEXT]
Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Psychiatry Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets.com's offering.

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of 569 psychiatry deals from 2019 to 2025. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where
[Source link]: https://www.globenewswire.com/news-release/2025/11/19/3191213/28124/en/Psychiatry-Collaboration-and-Licensing-Agreements-Analysis-Report-and-Directory-2025-Upfront-Milestone-and-Royalties-for-569-Deals-by-Company-A-Z-Therapy-Focus-and-Technology-Type.html


[TITLE]Immunology Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties of 900+ Deals by Company A-Z, Therapy Focus and Technology Type:
[TEXT]
Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

Fully revised and updated, the report provides details of 909 immunology deals from 2016 to 2025.

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the world's leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where
[Source link]: https://www.globenewswire.com/news-release/2025/11/19/3191172/28124/en/Immunology-Collaboration-and-Licensing-Agreements-Analysis-Report-and-Directory-2025-Upfront-Milestone-and-Royalties-of-900-Deals-by-Company-A-Z-Therapy-Focus-and-Technology-Type.html


===== Company info for companies mentioned in news =====

Company name: astellas
symbol: YPHA.F
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763687524
name: astellas
------------------------------------------------------------------

Company name: researchandmarkets.com
name: researchandmarkets.com
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=researchandmarkets.com&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: salarius
symbol: SLRX
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763687525
name: salarius
------------------------------------------------------------------

Company name: telix pharmaceuticals
name: telix pharmaceuticals
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=telix+pharmaceuticals&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

================================================================================

[TITLE]Polycystic Ovary Syndrome Treatment Market Expected to Reach USD 9.12 Bn by 2034:
[TEXT]
Ottawa, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The global polycystic ovary syndrome treatment
[Source link]: https://www.globenewswire.com/news-release/2025/11/19/3191206/0/en/Polycystic-Ovary-Syndrome-Treatment-Market-Expected-to-Reach-USD-9-12-Bn-by-2034.html


[TITLE]Immunology Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties of 900+ Deals by Company A-Z, Therapy Focus and Technology Type:
[TEXT]
Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

Fully revised and updated, the report provides details of 909 immunology deals from 2016 to 2025.

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the world's leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where
[Source link]: https://www.globenewswire.com/news-release/2025/11/19/3191172/28124/en/Immunology-Collaboration-and-Licensing-Agreements-Analysis-Report-and-Directory-2025-Upfront-Milestone-and-Royalties-of-900-Deals-by-Company-A-Z-Therapy-Focus-and-Technology-Type.html


[TITLE]Liver Failure Market Analysis Report 2025-2035: Gilead Sciences, AbbVie, and Boehringer Ingelheim Lead Advancements in Liver Failure Treatments and Artificial Liver Support Technologies:
[TEXT]
Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Liver Failure Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

The global liver failure market is experiencing steady growth, fuelled by increasing awareness of liver health, improved access to advanced healthcare facilities, and a growing range of therapeutic options. Liver transplantation remains the gold-standard treatment for end-stage liver failure, with outcomes improving due to advances in surgical techniques, organ preservation methods, and immunosuppressive therapy.

In addition, innovations in supportive care, such as artificial liver support systems (ALSS) and extracorporeal bioartificial liver devices, are extending survival in patients awaiting transplants. The development of pharmacological therapies targeting specific etiologies, such as antiviral agents for hepatitis B and C, anti-fibrotic drugs for NAFLD, and immune-modulating therapies for autoimmune hepatitis, is expanding the treatment landscape. Furthermore, the integration of regenerative medicine approaches, including stem cell therapy and bioengineered liver tissues, holds promise for reducing transplant dependency in the future.

Treatment options for liver failure continue to diversify. In acute cases, rapid interventions such as N-acetylcysteine for acetaminophen toxicity or urgent antiviral therapy for acute hepatitis can prevent progression to complete liver shutdown. For chronic liver failure, management focuses on controlling the underlying cause, preventing complications such as portal hypertension, and improving liver function through medications, dietary interventions, and lifestyle changes. Emerging technologies in hepatocyte transplantation and tissue engineering are being explored to provide temporary or permanent liver function restoration without the need for a donor organ. The trend toward personalized medicine, tailoring therapy based on genetic, metabolic, and lifestyle factors, is also gaining momentum in the liver failure market.

Despite advancements, the liver failure market faces several challenges. The shortage of donor organs remains the most significant barrier, with demand far outstripping supply in many countries. High costs associated with transplantation, artificial liver devices, and long-term immunosuppressive therapy limit access, particularly in low- and middle-income regions. Limited awareness of early liver disease symptoms contributes to late-stage diagnosis, where treatment options are more limited and less effective. Additionally, the complexity of managing comorbidities such as diabetes, obesity, and cardiovascular disease complicates treatment and increases healthcare costs. In rural and resource-limited settings, the lack of specialized hepatology centers and trained transplant teams further constrains patient outcomes.

Key players in the liver failure market include major healthcare and pharmaceutical companies such as Gilead Sciences, Inc., AbbVie Inc., and Boehringer Ingelheim, alongside transplant technology providers and medical device companies developing artificial liver support systems. These stakeholders are investing heavily in R&D to improve transplant success rates, develop novel anti-fibrotic and anti-inflammatory drugs, and bring bioartificial liver technologies to market. Strategic collaborations between academic research centers, biotechnology firms, and public health agencies are accelerating innovation and expanding treatment access. Patient advocacy groups and non-profit organizations are also playing a growing role in raising awareness, improving organ donation rates, and funding liver disease research.

The competitive landscape is characterized by both established pharmaceutical leaders and emerging biotechnology startups pursuing novel therapeutic pathways, including gene therapy for inherited liver conditions, RNA-based treatments for metabolic liver diseases, and immunomodulatory drugs to prevent transplant rejection. As research into regenerative medicine, stem cell applications, and artificial organ development progresses, the market is expected to diversify, offering patients more tailored and potentially curative options. With continued investment in diagnostics, donor management, and next-generation treatment modalities, the global liver failure market is poised for sustained growth, improving survival rates and quality of life for patients worldwide.

The global liver failure market is growing steadily, propelled by rising prevalence of chronic liver diseases such as viral hepatitis, alcohol-associated liver disease, and NAFLD/NASH, sustained improvements in care pathways, and broader awareness of liver health. Advances in therapeutics and interventions ranging from potent antivirals and anti-fibrotic candidates to optimized transplant surgery, machine-perfusion organ preservation, and artificial/bioartificial liver support systems are reshaping the treatment landscape by extending survival and bridging more patients to transplant.The rise of personalized medicine using genomics, phenotyping, and AI-driven risk stratification to tailor etiology-specific regimens and post-transplant immunosuppression is opening the door to more patient-centric solutions.

Expanding healthcare infrastructure and transplant capacity in emerging markets, alongside telehepatology and hub-and-spoke referral models, are increasing access to advanced care. As less invasive, more scalable diagnostics and supportive technologies become widely available, the liver failure market is positioned for continued expansion, underpinned by ongoing innovation across diagnostics, disease-modifying therapies, organ preservation, and patient management.

Key Topics Covered:

1. Global Liver Failure Market: Industry Analysis

1.1 Market Overview and Ecosystem

1.2 Epidemiological Analysis

1.3 Key Market Trends

1.4 Regulatory Landscape

1.5 Pipeline Analysis

1.6 Market Dynamics

1.6.1 Impact Analysis

1.6.2 Market Drivers

1.6.3 Market Restraints

1.6.4 Market Opportunities

2. Global Liver Failure Market, Region, $Million, 2024-2035

2.1 North America

2.1.1 Market Dynamics

2.1.2 Market Sizing and Forecast

2.1.2.1 North America Liver Failure Market, by Country ($ Million), 2024-2035

2.1.2.1.1 U.S.

2.1.2.1.2 Canada

2.2 Europe

2.2.1 Market Dynamics

2.2.2 Market Sizing and Forecast

2.2.2.1 Europe Liver Failure Market, by Country ($ Million), 2024-2035

2.2.2.1.1 U.K.

2.2.2.1.2 France

2.2.2.1.3 Germany

2.2.2.1.4 Italy

2.2.2.1.5 Spain

2.2.2.1.6 Rest-of-Europe

2.3 Asia-Pacific

2.3.1 Market Dynamics

2.3.2 Market Sizing and Forecast

2.3.2.1 Asia-Pacific Liver Failure Market, by Country, $Million, 2024-2035

2.3.2.1.1 Japan

2.3.2.1.2 Rest-of-Asia-Pacific

2.4 Rest-of-the-World

2.4.1 Market Dynamics

2.4.2 Market Sizing and Forecast

3. Global Liver Failure Market: Competitive Landscape and Company Profiles

3.1 Competitive Landscape

3.1.1 Mergers and Acquisitions

3.1.2 Partnership, Alliances and Business Expansion

3.1.3 New Offerings

3.1.4 Regulatory Activities

3.1.5 Funding Activities

3.2 Company Profiles

3.2.1 AbbVie Inc.

3.2.1.1 Overview

3.2.1.2 Top Products / Product Portfolio

3.2.1.3 Top Competitors

3.2.1.4 Target Customers/End-Users

3.2.1.5 Key Personnel

3.2.1.6 Analyst View

3.2.2 Akero Pharmeceuticals

3.2.3 Boehringer Ingelheim

3.2.4 Gilead Sciences, Inc.

3.2.5 Madrigal Pharmaceuticals

3.2.6 Viking Therapeutics

3.2.7 Zydus Pharmaceutical

3.2.8 Others

4. Research Methodology
[Source link]: https://www.globenewswire.com/news-release/2025/11/19/3191042/28124/en/Liver-Failure-Market-Analysis-Report-2025-2035-Gilead-Sciences-AbbVie-and-Boehringer-Ingelheim-Lead-Advancements-in-Liver-Failure-Treatments-and-Artificial-Liver-Support-Technologi.html


[TITLE]Inherited Retinal Disease Market Analysis Report 2025-2035, Featuring Profiles of Novartis, GenSight Biologics, Aldeyra Therapeutics, and Spark Therapeutics:
[TEXT]
Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Inherited Retinal Disease Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

The global inherited retinal disease market is projected to experience significant growth, reaching substantial valuation in 2025, with an expected steady compound annual growth rate (CAGR) during the forecast period from 2025 to 2035.

This growth is driven by the rising prevalence of retinal diseases and advancements in genetic and cell-based therapies. Inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, and Stargardt disease, are progressive genetic disorders that lead to vision loss. With the advent of gene therapies and stem cell treatments, the market for inherited retinal disease treatments is set to undergo a transformation.

The growing emphasis on precision medicine, which tailors treatments to individual genetic mutations, is also a major driver for the market. As new treatments emerge, more patients will have access to personalized therapies that significantly enhance their quality of life. However, the cost of advanced treatments remains a significant barrier, limiting access for many patients, especially in low-income regions.

Opportunities for growth in the inherited retinal disease market include the growing access to treatments in emerging markets, which offer substantial potential. Additionally, the development of combination therapies can improve treatment outcomes for complex inherited retinal diseases. Major market trends include stem cell therapies and regenerative treatments, which offer new possibilities for repairing retinal damage. Key drivers of growth include new gene therapies and tailored treatments, which are revolutionizing the market and providing potential cures for inherited retinal diseases. Furthermore, better healthcare infrastructure, particularly in developing countries, is making specialized care more accessible, expanding the market's reach.

North America is expected to maintain a dominant share of the global inherited retinal disease market, driven by advanced healthcare systems, strong R&D, and high awareness. Europe will experience steady growth, supported by research investments and government support for rare disease treatments. The Asia-Pacific region is projected to grow rapidly due to an aging population, rising healthcare investments, and improved access to retinal disease treatments.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The report provides comprehensive insights into the current trends in gene therapy, stem cell-based treatments, and genetic screening, helping companies identify product development opportunities. Companies can leverage these insights to design therapies that cater to the specific genetic mutations responsible for inherited retinal diseases.

Competitive Strategy: Maintain a competitive edge, companies in the global inherited retinal disease market should focus on advancing the safety and efficacy of existing therapies, exploring new drug delivery methods, and fostering collaborations with research institutions. Additionally, focusing on personalized treatment approaches and expanding access to genetic testing could be key strategies for growth.

Key Market Players and Competition Synopsis

The companies profiled in this report are based on extensive research and insights from primary experts, evaluating company coverage, product portfolios, and market penetration. The leading players in the global inherited retinal disease market include pharmaceutical companies and biotechnology firms making significant advancements in therapies for retinal disorders. These companies are at the forefront of addressing unmet needs and pushing the boundaries of treatment options for inherited retinal disease.

Demand - Drivers and Limitations

The demand drivers for the global inherited retinal disease market are:

New treatments like gene therapy and tailored treatments are revolutionizing the market, offering potential cures for inherited retinal diseases.

Better healthcare infrastructure, especially in developing countries, is making specialized care more accessible.

Limitations:

The cost of advanced treatments remains a significant barrier, limiting access for many patients.

Some of the prominent companies established in the global inherited retinal disease market include:

Novartis AG

GenSight Biologics

Aldeyra Therapeutics

Spark Therapeutics (F. Hoffmann-La Roche AG)

Key Topics Covered:

1. Global Inherited Retinal Disease Market: Industry Outlook

1.1 Market Overview and Ecosystem

1.2 Epidemiological Analysis of Inherited Retinal Disease Market

1.3 Market Trends

1.4 Clinical Trials Analysis

1.5 Regulatory Landscape Analysis

1.6 Market Dynamics

1.6.1 Impact Analysis

1.6.2 Market Drivers

1.6.3 Market Restraints

1.6.4 Market Opportunities

2. Global Inherited Retinal Disease Market (by Region), $Million, 2024-2035

2.1 North America

2.1.1 Market Dynamics

2.1.2 Market Sizing and Forecast

2.1.2.1 North America Inherited Retinal Disease Market (by Country)

2.1.2.1.1 U.S.

2.2 Europe

2.2.1 Market Dynamics

2.2.2 Market Sizing and Forecast

2.2.2.1 Europe Inherited Retinal Disease Market (by Country)

2.2.2.1.1 Germany

2.2.2.1.2 France

2.2.2.1.3 Italy

2.2.2.1.4 U.K.

2.3 Asia-Pacific

2.3.1 Market Dynamics

2.3.2 Market Sizing and Forecast

2.3.2.1 Asia-Pacific Inherited Retinal Disease Market (by Country)

2.3.2.1.1 Japan

2.4 Rest-of-the-World

2.4.1 Market Dynamics

2.4.2 Market Sizing and Forecast

3. Global Inherited Retinal Disease Market Competitive Benchmarking and Company Profiles

3.1 Key Strategies and Developments by Company

3.1.1 Funding Activities

3.1.2 Mergers and Acquisitions

3.1.3 Regulatory Approvals

3.1.4 Partnerships, Collaborations and Business Expansions

3.2 Company Profiles

3.2.1 Novartis AG

3.2.1.1 Company Overview

3.2.1.2 Product Portfolio

3.2.1.3 Target Customers/End Users

3.2.1.4 Key Personnels

3.2.1.5 Analyst View

3.2.2 GenSight Biologics

3.2.3 Aldeyra Therapeutics

3.2.4 Spark Therapeutics (F. Hoffmann-La Roche AG)

4. Research Methodology
[Source link]: https://www.globenewswire.com/news-release/2025/11/19/3191048/28124/en/Inherited-Retinal-Disease-Market-Analysis-Report-2025-2035-Featuring-Profiles-of-Novartis-GenSight-Biologics-Aldeyra-Therapeutics-and-Spark-Therapeutics.html


===== Company info for companies mentioned in news =====

Company name: abbvie
symbol: ABBV
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763687527
name: abbvie
------------------------------------------------------------------

Company name: boehringer ingelheim
name: boehringer ingelheim
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: gilead sciences
symbol: GILD
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763687528
name: gilead sciences
------------------------------------------------------------------

Company name: novartis
symbol: NVS
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763687530
name: novartis
------------------------------------------------------------------

================================================================================

No articles found for this sector...

================================================================================

